Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

Asmacure closes US$9 million Series A financing

Reading Time 1 minute read Subscribe


On May 8, 2007, Asmacure Ltée announced that it had closed a Series A round of financing of US$9 million utilizing an exchangeable shares structure involving Fonds Bio-Innovation and Innovatech Québec Chaudière-Appalaches from Québec City, and Domain Associates from Princeton, New Jersey. This investment will support Asmacure's operations and R & D program through the preclinical and initial clinical development of its Lead Compound aimed at a new pharmacological approach for the treatment of asthma. Asmacure was advised in this financing by a team from Fasken Martineau led by François Duchesneau and that included, among others, René Roy, Marie Carole Tétrault and Jean-Gabriel L'Ecuyer in Québec City and Martin Fisher-Haydis in Toronto.


    Receive email updates from our team